Daily non-political popular news in brief.

Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial

Heart attacks are caused by a build-up and instability of plaque in the coronary arteries, which is often a result of chronic inflammation of the blood vessel walls. A study presented today at the American College of Cardiology's 56th Annual Scientific Session assessed whether adding a novel agent with antioxidant and anti-inflammatory properties to optimal medical therapy would reduce coronary events and death among patients with heart disease.

Read more »

Keywords: novel, anti-oxidant, anti-inflammatory, agent, shows, effectiveness, key, endpoints, trial, anti, oxidant, inflammatory, show, endpoint

« Previous | Next »

Similar news on "Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial":

1. Study finds lapatinib shows promise as therapy for inflammatory breast cancer
   12-14-2006 · EurekAlert!
   In the first multi-center clinical trial conducted to better understand the complexities of a rare, aggressive and often lethal form of breast cancer, researchers have discovered that the experimental biological agent, lapatinib, successfully and specifically treats inflammatory breast cancer (IBC).
   Similar news · Read more »
   
2. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
   11-15-2007 · EurekAlert!
   Advanced Life Sciences Holdings, Inc. today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia, the sixth leading cause of death in the United States.
   Similar news · Read more »
   
3. Immune cell communication key to hunting viruses, Jefferson immunologists show
   10-25-2006 · EurekAlert!
   Immunologists have used nanotechnology to create a novel "biosensor" to solve in part a perplexing problem in immunology: how the immune system's killer T-cells hunt down invading viruses. They have found that surprisingly little virus can turn on killer T-cells, thanks to some complicated communication among "antigen presenting" proteins that recognize and attach to the virus, making it visible to the immune system. Presenting proteins cooperate, spreading a signal among receptors and boosting T-cell response.
   Similar news · Read more »
   
4. Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
   01-31-2008 · EurekAlert!
   Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
   Similar news · Read more »
   
5. Is there a role for serial outpatient drug infusions in advanced heart failure?
   03-25-2007 · EurekAlert!
   For patients with severe chronic heart failure, known as stage D or chronic decompensated heart failure (CDHF), hospitalization is frequent and treatment options are limited. The FUSION II trial (Follow-Up Serial Infusions of Nesiritide in Advanced Heart Failure) tested the benefit of a novel drug infusion regimen of serial administration of nesiritide (NES) versus placebo in outpatients with advanced heart failure and a primary endpoint of all cause mortality and cardiorenal hospitalizations.
   Similar news · Read more »
   
6. Other highlights in the Oct. 30 JNCI
   10-30-2007 · EurekAlert!
   Also in the Oct. 30 JNCI -- a cancer-killing virus that may be used to treat metastatic cancer, the risk of second cancers in cervical cancer survivors, a novel trial design that shows which cancer treatments are the most promising, and a review on brain cancer therapies that target normal brain cells too.
   Similar news · Read more »
   
7. Shrinkage of prostate led to overestimation of cancer risk in trial
   09-12-2007 · EurekAlert!
   Reanalysis of data from the Prostate Cancer Prevention Trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.
   Similar news · Read more »
   
8. Novel MS drug shows promise in 2 lethal leukemias
   08-28-2007 · EurekAlert!
   A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia or acute lymphocytic leukemia, and whose cancer cells show a particular genetic change called the Philadelphia chromosome.
   Similar news · Read more »
   
9. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
   06-02-2007 · EurekAlert!
   The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).
   Similar news · Read more »
   
10. Once-yearly treatment significantly reduces bone fractures in women with postmenopausal osteoporosis
    05-02-2007 · EurekAlert!
    Phase III clinical trial shows effectiveness of once-yearly treatment for postmenopausal osteoporosis.
    Similar news · Read more »